Evaluation of the Safety, Tolerability and Immunogenicity of an Oral, Inactivated Whole

[1]  T. Farag,et al.  Shigella Isolates From the Global Enteric Multicenter Study Inform Vaccine Development , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  A. L. Bourgeois,et al.  Development and Preclinical Evaluation of a Trivalent, Formalin-Inactivated Shigella Whole-Cell Vaccine , 2014, Clinical and Vaccine Immunology.

[3]  Y. Takeda,et al.  Protective immunity by oral immunization with heat‐killed Shigella strains in a guinea pig colitis model , 2013, Microbiology and immunology.

[4]  Inacio Mandomando,et al.  Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study , 2013, The Lancet.

[5]  M. Levine,et al.  Progress and pitfalls in Shigella vaccine research , 2013, Nature Reviews Gastroenterology &Hepatology.

[6]  J. Bream,et al.  Differential serum cytokine responses to inactivated and live attenuated seasonal influenza vaccines. , 2012, Cytokine.

[7]  A. Naheed,et al.  Decreasing Shigellosis-related Deaths without Shigella spp.–specific Interventions, Asia , 2010, Emerging infectious diseases.

[8]  J. D. Di Santo,et al.  Th17 Cells Are the Dominant T Cell Subtype Primed by Shigella flexneri Mediating Protective Immunity , 2010, The Journal of Immunology.

[9]  E. Oaks,et al.  Inactivated and subunit vaccines to prevent shigellosis , 2009, Expert review of vaccines.

[10]  J. Crump,et al.  Part II. Analysis of data gaps pertaining to Shigella infections in low and medium human development index countries, 1984–2005 , 2007, Epidemiology and Infection.

[11]  D. Sack,et al.  Increasing Spectrum in Antimicrobial Resistance of Shigella Isolates in Bangladesh: Resistance to Azithromycin and Ceftriaxone and Decreased Susceptibility to Ciprofloxacin , 2007, Journal of health, population, and nutrition.

[12]  R. Walker,et al.  Vaccine potential for inactivated shigellae. , 2007, Vaccine.

[13]  M. Wolf,et al.  Two Studies Evaluating the Safety and Immunogenicity of a Live, Attenuated Shigella flexneri 2a Vaccine (SC602) and Excretion of Vaccine Organisms in North American Volunteers , 2004, Infection and Immunity.

[14]  M. Abreu,et al.  Decreased Expression of Toll-Like Receptor-4 and MD-2 Correlates with Intestinal Epithelial Cell Protection Against Dysregulated Proinflammatory Gene Expression in Response to Bacterial Lipopolysaccharide1 , 2001, The Journal of Immunology.

[15]  A. Trofa,et al.  Dr. Kiyoshi Shiga: discoverer of the dysentery bacillus. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  P. Sansonetti,et al.  Vaccination against Shigellosis with Attenuated Shigella flexneri 2a Strain SC602 , 1999, Infection and Immunity.

[17]  D. Mahalanabis,et al.  Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis , 1999, Acta paediatrica.

[18]  K. Schön,et al.  Interferon‐γ receptor‐deficient mice exhibit impaired gut mucosal immune responses but intact oral tolerance , 1997, Immunology.

[19]  J. Olson,et al.  Characteristics of Shigella sonnei infection of volunteers: signs, symptoms, immune responses, changes in selected cytokines and acute-phase substances. , 1995, The American journal of tropical medicine and hygiene.

[20]  S. Szu,et al.  Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. , 1995, The Journal of infectious diseases.

[21]  M. Levine,et al.  Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen , 1992, Infection and immunity.

[22]  Y. Lerman,et al.  Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide. , 1992, The Journal of infectious diseases.

[23]  M. Levine,et al.  Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. , 1991, American journal of epidemiology.

[24]  A. Kantele.  Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. , 1990, Vaccine.

[25]  M. Levine,et al.  Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. , 1990, Vaccine.

[26]  D. Sack,et al.  Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. , 1988, The Journal of infectious diseases.

[27]  T. L. Hale,et al.  Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp , 1986, Infection and immunity.

[28]  A. A. Reeder,et al.  Antibody-dependent cell-mediated antibacterial activity: K lymphocytes, monocytes, and granulocytes are effective against shigella. , 1980, Journal of immunology.

[29]  D. Swerdlow,et al.  Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. , 1999, Bulletin of the World Health Organization.

[30]  M. Levine,et al.  A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. , 1995, Vaccine.

[31]  A. Lindberg,et al.  Serum IgG antibody responses to Shigella invasion plasmid-coded antigens detected by immunoblot. , 1994, Scandinavian journal of infectious diseases.

[32]  H. Dupont,et al.  Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. , 1972, The Journal of infectious diseases.

[33]  E. Gangarosa,et al.  Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains. , 1971, Bulletin of the World Health Organization.